Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SoftMedX Healthcare's Debt-to-EBITDA or its related term are showing as below:
CCWYF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -37.64 Med: -1.43 Max: 288.95
Current: 0.11
During the past 13 years, the highest Debt-to-EBITDA Ratio of SoftMedX Healthcare was 288.95. The lowest was -37.64. And the median was -1.43.
CCWYF's Debt-to-EBITDA is ranked better than 92.29% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs CCWYF: 0.11
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SoftMedX Healthcare Debt-to-EBITDA Related Terms
SoftMedX Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SoftMedX Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, SoftMedX Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SoftMedX Healthcare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SoftMedX Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SoftMedX Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
SoftMedX Healthcare (CCWYF) has a Debt-to-EBITDA of 0.11 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SoftMedX Healthcare. According to the industry distribution chart, SoftMedX Healthcare ranks #37 out of 480 companies in the Healthcare Providers & Services industry, placing it in the top 7.7%.
Is SoftMedX Healthcare's Debt-to-EBITDA too high?
SoftMedX Healthcare's current Debt-to-EBITDA is 0.11. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. SoftMedX Healthcare's value of 0.11 is 95% below this industry median. Based on the distribution chart, SoftMedX Healthcare ranks #37 out of 480 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, SoftMedX Healthcare has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does SoftMedX Healthcare's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, SoftMedX Healthcare ranks #37 out of 480 companies for Debt-to-EBITDA. This places SoftMedX Healthcare in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.19. SoftMedX Healthcare's value of 0.11 is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SoftMedX Healthcare's current Debt-to-EBITDA of 0.11 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SoftMedX Healthcare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SoftMedX Healthcare's current Debt-to-EBITDA is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SoftMedX Healthcare stock overvalued right now?
SoftMedX Healthcare (CCWYF) has a current Debt-to-EBITDA of 0.11. The stock's GF Value™ is $2.99, compared to a current price of $0.70 — trading 76.6% below its estimated fair value. The current Debt-to-EBITDA is 0.11 and 95% below the Healthcare Providers & Services industry median of 2.19. SoftMedX Healthcare's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SoftMedX Healthcare (CCWYF), the current Debt-to-EBITDA is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SoftMedX Healthcare (CCWYF) Overvalued in 2026?
Based on GuruFocus' analysis, SoftMedX Healthcare stock appears to be undervalued.
The current stock price of $0.70 is trading 76.6% below its estimated GF Value™ of $2.99.
Key valuation signals for CCWYF:
Debt-to-EBITDA: 0.11
GF Value™: $2.99 vs. price of $0.70 (76.6% below fair value)
Industry Position: 95% below the Healthcare Providers & Services median (#37 of 480)
No single metric tells the full story. See the CCWYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SoftMedX Healthcare Ltd is principally engaged in the distribution of medical and healthcare equipment and products. The Group has one reportable operating segment: medical and well-being business, for the Distribution of medical and healthcare equipment and products.
54GF Score
Get the complete analysis for CCWYF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCWYF has been successfully added to your 
